dihexa approval status fda Peptide Therapy Dihexa Peptide: Unlocking Brain Repair,

Three questions are worth carrying over to the next unlicensed peptide somebody markets to you

It's well-tolerated with minimal side effects

Phase 3 data showed lower rates of nausea and vomiting compared to GLP-1 therapiespotentially better tolerated for some patients

Discontinuation due to adverse events was about 4% across all dose groups

In a multicenter, randomized, placebo-controlled dose-finding trial, cagrilintide at doses ranging from 0.3 to 4.5 mg weekly produced dose-dependent weight reductions, with the 4.5 mg dose achieving approximately 10.8% weight loss at 26 weeks compared to 3.0% with placebo

Further, dihexa and Nle1-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself